Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia.

Maruyama T, Higuchi T, Yamazaki T, Okawa E, Ando H, Oikawa O, Inoshita A, Okada K, Abe M.

Cardiorenal Med. 2017 Jun;7(3):188-197. doi: 10.1159/000462983. Epub 2017 Apr 20.

2.

Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map.

Abe M, Okada K, Maruyama N, Takashima H, Oikawa O, Soma M.

J Diabetes Res. 2016;2016:5374746. doi: 10.1155/2016/5374746. Epub 2015 Dec 29.

3.
4.

Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial.

Higuchi T, Abe M, Yamazaki T, Okawa E, Ando H, Hotta S, Oikawa O, Kikuchi F, Okada K, Soma M.

Am J Kidney Dis. 2016 Feb;67(2):260-70. doi: 10.1053/j.ajkd.2015.09.010. Epub 2015 Oct 23.

PMID:
26508680
5.

Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis.

Higuchi T, Abe M, Mizuno M, Yamazaki T, Suzuki H, Moriuchi M, Oikawa O, Okawa E, Ando H, Okada K.

Sleep Med. 2015 Aug;16(8):941-8. doi: 10.1016/j.sleep.2015.03.025. Epub 2015 May 8.

PMID:
26070856
6.

Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.

Abe M, Maruyama N, Oikawa O, Maruyama T, Okada K, Soma M.

Scand J Clin Lab Invest. 2015 Sep;75(5):421-7. doi: 10.3109/00365513.2015.1054871. Epub 2015 Jun 12.

PMID:
26067610
7.

Low-density lipoprotein apheresis for corticosteroid-resistant skin lesions caused by cholesterol crystal embolism: a case report and review of the literature.

Kobayashi H, Abe M, Murata Y, Maruyama T, Furukawa T, Oikawa O, Okada K.

J Artif Organs. 2015 Sep;18(3):285-9. doi: 10.1007/s10047-015-0830-4. Epub 2015 Mar 28.

PMID:
25821197
8.

Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial.

Higuchi T, Abe M, Yamazaki T, Mizuno M, Okawa E, Ando H, Oikawa O, Okada K, Kikuchi F, Soma M.

Nutrients. 2014 Dec 22;6(12):5992-6004. doi: 10.3390/nu6125992.

9.

Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.

Abe M, Oikawa O, Okada K, Soma M.

J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):159-64. doi: 10.1177/1470320314551443. Epub 2014 Oct 6.

PMID:
25287898
10.

Randomized trial of frequent low-efficiency and short hemodialysis/hemofiltration in hemodialysis patients with acute brain injury.

Okada K, Abe M, Takashima H, Baba S, Taniguchi M, Suzuki H, Yoshida Y, Oikawa O, Maruyama N, Soma M.

Int J Artif Organs. 2013 Nov;36(11):793-802. doi: 10.5301/ijao.5000249. Epub 2013 Oct 2.

PMID:
24338654
11.

Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis.

Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N, Matsumoto K.

Clin Exp Nephrol. 2007 Dec;11(4):304-308. doi: 10.1007/s10157-007-0499-y. Epub 2007 Dec 21.

PMID:
18085392
12.

A case report of hemodialysis intolerance with eosinophilia.

Higuchi T, Yamazaki T, Ohnishi Y, Matsumoto S, Yabuki M, Kitajima S, Toshida Y, Maruyama N, Oikawa O, Okada K, Fukuda N, Soma M, Matsumoto K.

Ther Apher Dial. 2007 Feb;11(1):70-3.

PMID:
17309578
13.

Correction of copper deficiency improves erythropoietin unresponsiveness in hemodialysis patients with anemia.

Higuchi T, Matsukawa Y, Okada K, Oikawa O, Yamazaki T, Ohnishi Y, Fujita T, Fukuda N, Soma M, Matsumoto K.

Intern Med. 2006;45(5):271-3. Epub 2006 Apr 3.

14.

The influence of uremic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells.

Higuchi T, Fukuda N, Yamamoto C, Yamazaki T, Oikawa O, Ohnishi Y, Okada K, Soma M, Matsumoto K.

Ther Apher Dial. 2006 Feb;10(1):65-71.

PMID:
16556139

Supplemental Content

Loading ...
Support Center